myocardial infarction, and renal failure have prompted caution regarding nonsteroidal antiinflammatory drug use. In contrast, prior studies suggested safe perioperative use of common nonsteroidal antiinflammatory drugs, such as ketorolac and ibuprofen, in plastic surgery. 8, 9 Reversible, nonselective nonsteroidal antiinflammatory drugs function by temporarily inhibiting the cyclooxygenase enzymes. As a result, these medications are effective analgesics and antiinflammatory drugs. However, platelet aggregation is also temporarily inhibited, which prompts concern for the ability to achieve surgical hemostasis. In addition, there is little evidence on the effect of nonsteroidal antiinflammatory drugs on other perioperative complications.
Ketorolac, a potent, nonselective, nonsteroidal antiinflammatory drug available most commonly in intravenous forms, has been documented to provide excellent postoperative analgesia for a variety of surgical procedures; however, like other nonsteroidal antiinflammatory drugs, side effect concerns limit use. A few prior studies on patients undergoing surgery have found that ketorolac is generally safe with regard to bleeding. 8, 10, 11 However, these studies are mostly underpowered, retrospective, include nonsystemic forms of ketorolac delivery, or are not in pertinent patient populations. For example, a recent meta-analysis of ketorolac restricted to plastic surgery patients has not demonstrated an increased risk for hematoma, but this analysis included a mix of studies with different administration routes, including both topical and systemic. [11] [12] [13] Excluding the topical use of ketorolac, the two largest studies included in the pooled data were retrospective chart reviews and the conclusions differed. 10, 14 The escalation of opioid use in the United States has illuminated the need for safe, nonaddictive, nonsedating analgesics. Ketorolac, like other reversible nonsteroidal antiinflammatory drugs, has the potential to be a useful analgesic if its safety can be confirmed. A small group of prior studies tested the efficacy and safety of ketorolac, but no study has definitively characterized the postoperative risks. 8, 10, 11, [14] [15] [16] [17] However, concurrent with the consensus studies, there is growing comfort with the idea that ketorolac is likely safe in most operations in healthy patients. To date, no national or population-based studies have been conducted on nonsteroidal antiinflammatory drugs in the postoperative period. Given the lack of power in prior work and to further elucidate the safety and practice patterns of ketorolac in the United States, we evaluated insurance claims from a national database seeking to evaluate national practice patterns in common body contouring operations, including lipectomy and breast reduction. We chose to focus on body contouring procedures because of the relatively high risk and high sensitivity for hematomas in this patient population. 18 Furthermore, we aimed to evaluate the differences in complication occurrence, need for reoperation, and hospital length of stay for patients who received ketorolac perioperatively. We hypothesized that there would be no difference in morbidity between the groups after surgery.
PATIENTS AND METHODS

Data Source and Study Cohort
This study qualified as exempt by the institutional review board. We used the Truven MarketScan Commercial Claims and Encounters and Medicare Supplement and Coordination of Benefits (MarketScan; Truven Health Analytics, Ann Arbor, Mich.) inpatient and outpatient encounters between January 1, 2009, and December 31, 2014. 19 The MarketScan databases contain a national sample of beneficiaries and dependents from large employers and government and public organizations. The database includes patientspecific health care encounters, timing of care, health care cost, and health plan details for over 55 million enrollees annually. Each patient in the database has a unique identification number, which allows them to be followed longitudinally through enrollment in the included health plan. Patients included were aged 18 years or older and undergoing an outpatient body contouring operation as identified by CPT codes for body contouring procedures, including lipectomy, liposuction, and breast procedures. Appendix 1 provides a comprehensive list of International Classification of Diseases, Ninth Revision, and CPT codes used to identify and extract data. (See Appendix, Supplemental Digital Content 1, which shows the study code definitions, http://links.lww.com/PRS/C967.)
A total of 158,849 patients met criteria between January 1, 2009, and September 30, 2014. No patients were enrolled after September 30, 2014, to capture at least 90 days of postoperative enrollment within the database (Fig. 1 ). Patients were excluded if there was lack of continuous enrollment during the study period, lack of pharmacologic records, claims for systemic anticoagulation (including heparin, low-molecular-weight heparin, warfarin, argatroban, or clopidogrel) within 30 days before surgery, any prescription Plastic and Reconstructive Surgery • October 2018 nonsteroidal antiinflammatory drug within 7 days before surgery (including aspirin), age younger than 18 years, or any of the complications of interest in the week before surgery. Medication exposure was defined by National Drug Codes for each medication in addition to Healthcare Common Procedure Coding System procedure-related J codes for infusion or injections.
Ketorolac Exposure
Patients included in the study cohort were enrolled for a minimum of 1 month before and 3 months after the index surgery. Patients were selected for exposure to intravenous ketorolac claims within 48 hours after surgery, excluding exposure on readmission to the hospital for complications. Exposure to ketorolac was defined by J-1885 (injection, ketorolac tromethamine, per 15 mg) and National Drug Codes. (See Appendix, Supplemental Digital Content 2, which shows the nonsteroidal antiinflammatory drug and ketorolac exposure, http://links.lww.com/PRS/C968.)
Outcome Variables
Patients were followed for 90 days from their index operation for complications, readmission for any reason, readmission for pain, reoperation for any reason, and readmission specific to hematoma washout (see Appendix, Supplemental Digital Content 1, http://links.lww.com/PRS/C967). A subanalysis of readmissions was performed to analyze the rates of admission for either a primary or secondary diagnosis of pain. The dosage of ketorolac was assessed for a difference in rates of complications comparing low-dose intravenous ketorolac (15 mg) to high-dose intravenous ketorolac (≥30 mg). Complications included hematoma, seroma, infection, acute kidney injury, venous thrombosis, pulmonary embolism, myocardial infarction, and blood transfusion. Other 
Patient Attributes and Demographics
Patient attributes included sex, age, geographic region, insurance type, income level, and associated comorbidities. Patient comorbidities were stratified using the Elixhauser Comorbidity Index. [20] [21] [22] International Classification of Diseases, Ninth Revision, codes were used to examine all health care claims for the presence of 30 relevant patient comorbidities. (See Appendix, Supplemental Digital Content 5, which shows the Elixhauser Comorbidity Index, http://links.lww.com/ PRS/C971.)
Statistical Analysis
We used descriptive statistics to summarize the characteristics of the cohort, including sex, age, median income, region, comorbidities, smoking status, type of surgery, anticoagulation medications within 30 days after surgery, and treatment with intravenous forms of antibiotics within 30 days after surgery. Given the size of the sample, we used standard differences to examine the baseline characteristics between patients receiving ketorolac within 48 hours after surgery compared with patients not receiving ketorolac. A difference of less than 0.1 was used to indicate a negligible difference in the mean or prevalence of a covariate between treatment groups. 23 We calculated the standard difference in addition to the chi-square test because sample size influences the p value even though the difference is very small between two groups. We used logistic regression to calculate an odds ratios to identify the complication risk associated with perioperative ketorolac use. Covariates for logistic regression were selected based on significant differences between groups in univariate statistics and for specific conditions known to be associated with the outcome under analysis. For example, hematoma was used as a covariate for seroma, but both hematoma and seroma were excluded as covariates for reoperation, as these are both potential causes for this outcome. Fisher's exact test was used to calculate differences in readmission diagnoses. We also calculated the adjusted odds ratio with adjustment for age, sex, median income, region, Elixhauser Comorbidity Index, hypertension, deep venous thrombosis, pulmonary embolism, tobacco use, other anticoagulation (e.g., clopidogrel, enoxaparin, warfarin, heparin, aspirin), surgery type, and hematoma when looking at other outcomes. All tests were performed using a two-sided significance level for a value of p < 0.05.
RESULTS
Study Cohort
The total cohort was 106,279 patients after all exclusion and inclusion criteria were satisfied. Of these, 4924 patients (4.6 percent) received perioperative ketorolac, and 101,355 (95.4 percent) received no ketorolac ( Table 1 ). The study demographic had a few baseline differences. The cohort receiving ketorolac demonstrated a small difference in age (45.2 years versus 47.6 years; SD = 0.21; p < 0.001). Ketorolac patients had a small difference in annual income (mean income, $52,100 versus $53,000; SD = $1900; p < 0.001). Finally, patients receiving ketorolac had a small difference in specific operations performed (lipectomy, 21.4 percent versus 14.7 percent; breast reduction, 76.7 percent versus 77.5 percent; head and neck procedures, 1.9 percent versus 7.9 percent; SD = 0.32; p < 0.001). Patients receiving ketorolac were geographically more likely to be in the northeast or north central United States (p < 0.001), but this was negligible by standard difference (SD = 0.099). There was a small difference between patient comorbidities according to the Elixhauser Comorbidity Index, with ketorolac patients tending to have a higher comorbidity score (SD = 0.049; p = 0.008). A small difference in rate of hypertension was noted between the groups (26.3 percent versus 29.3 percent; SD −0.068; p < 0.001). Smoking was more common in patients receiving ketorolac (6.2 percent versus 3.9 percent; SD = 0.10; p < 0.001). Overall, the cohort was similar with respect to receiving anticoagulation postoperatively, comorbid conditions, and sex.
Risk for Complications and Reoperation
A small difference in absolute risk of International Classification of Diseases, Ninth Revision, diagnosis of hematoma was noted for patients receiving ketorolac versus the control group (2.3 percent versus 1.7 percent; p = 0.002), and a number needed to harm calculation suggests that over Plastic and Reconstructive Surgery • October 2018 172 patients would require ketorolac before the occurrence of an additional hematoma event (Table 2) . Hematoma occurred more frequently in patients receiving ketorolac compared to controls within 72 hours of surgery (1.2 percent versus 0.9 percent; p = 0.036) and between 3 and 30 days after surgery (1.2 percent versus 0.9 percent; p = 0.036). There was a small difference in risk for seroma in the ketorolac group (2.1 percent versus 1.5 percent; p < 0.001) and a number needed to harm calculation of 167 patients. For acute kidney injury (0.1 percent versus 0.2 percent; p = 0.09), need for a blood transfusion (0.1 percent versus 0.1 percent; p = 0.51), or myocardial infarction (0.02 percent versus 0.04 percent; p = 0.72) within 30 days of surgery, there was no significant difference between ketorolac compared to controls. There was a significant difference in rates of readmission favoring ketorolac (adjusted OR, 0.53; 95 percent CI, 0.28 to 0.99). A multivariable logistic regression analysis was performed for rates of hematoma and seroma (Table 3 ). No significant difference was detected for hematoma within 30 days of surgery (adjusted OR, 1.20; 95 percent CI, 0.99 to 1.46). In multivariable regression, seroma was more common with ketorolac use (adjusted OR, 1.28; 95 percent CI, 1.05 to 1.57).
Reoperation for any reason within 72 hours of surgery was more frequent in patients receiving ketorolac compared with control patients (2.5 percent versus 1.8 percent; p < 0.001). After multivariable regression, this effect remained significant (OR, 1.22; 95 percent CI, 1.00 to 1.49; p < 0.05), with a number needed to harm of approximately 262 patients before a reoperation event. Reoperation for a diagnosis of hematoma was also more common with ketorolac, but the absolute difference was small (0.6 percent versus 0.4 percent; p = 0.009). In contrast, the ketorolac group was readmitted to the hospital less frequently compared with the control group (3.1 percent versus 5.0 percent; p < 0.001). The rate (Table 4) . Most patients received only 15 mg of ketorolac (89.1 percent), whereas a minority received higher dosing (10.9 percent). For low-dose versus high-dose ketorolac, there was no difference in rate of hematoma (2.2 percent versus 2.9 percent; p = 0.30) or reoperation (2.5 percent versus 2.1 percent; p = 0.52). There were no differences in rates of renal complications 
DISCUSSION
Our data suggest that when controlling for demographics and patient comorbidities, there is no difference in rate of hematoma with ketorolac use. However, before multivariable regression, a small absolute difference in the risk for hematoma was noted (1.2 percent versus 0.9 percent; p = 0.036; number needed to harm, 424 patients). Ketorolac was also associated with a small increase in risk for reoperation for any cause within 72 hours. Within 72 hours of surgery, the most likely reason for reoperation would be hematoma, but we cannot rule out ketorolac use in some of these cases as additional analgesia in the setting of multiple operations. By number needed to harm calculations, over 262 patients would need to be treated with ketorolac before incurring any additional operation. This suggests that even though a subtle difference may exist, the effect of this difference is likely of minimal clinical importance. In contrast, patients who did not receive ketorolac were significantly more likely to require readmission to the hospital and had longer hospital stays. Finally, at least one prior study demonstrated a higher rate of hematoma in breast reduction with delivery of 30 mg of intravenous ketorolac in recovery.
14 In our cohort, we found no difference in rates of hematoma between low (15 mg) or high (≥30 mg) doses of ketorolac.
To date, there is little population-based evidence regarding the risk of postoperative complications and the safety of ketorolac in perioperative care. One meta-analysis found no difference in bleeding with ketorolac, but this meta-analysis combined primary studies across a broad spectrum of surgical fields with variable risks for bleeding. 8 Another recent systematic review considered primary studies in plastic surgery with multiple routes of ketorolac administration and found that the medication was generally safe in aesthetic procedures. 11 For this study, we chose to focus on breast reduction and body contouring given the large surface area involved in the surgical field and the relatively high risk for hematoma in this population. Body contouring is particularly susceptible to hematoma formation, and postoperative hematoma is a catastrophic complication when unnoticed. For example, a recent nationwide cohort of postbariatric abdominoplasty patients had a rate of postoperative blood transfusion of 9.3 percent. This example highlights both the potential rate of hematoma and volume of blood loss that can occur in breast or body contouring procedures. 18 Our cost analysis estimates the average cost difference for ketorolac use across the entire cohort to be a savings of approximately $157 per patient, or over $16 million in total. This figure considers the difference in cost given the odds of both reoperation and readmission events. Given the push toward bundled payments and changes in health care payor characteristics, use of ketorolac appears to have a practical savings that will save the average patient both time in the hospital and overall cost. Although not a focus of this analysis, nonsteroidal antiinflammatory drugs have been shown across multiple studies to be effective in multimodal analgesia. There could be additional ketorolac-related cost reduction if multimodal analgesia results in fewer narcotic refills. New persistent opiate use after surgery has rates between 5 and 7 percent in both minor and major surgical procedures. 24 The need for alternative medications has become even more pressing given national attention regarding the so-called opioid crisis. 25 Use of nonnarcotic medications such as ketorolac may help to further reduce the overall need for narcotics.
Interestingly, our data do suggest an increased rate of reoperation in patients who do develop a postoperative hematoma. Reversible cyclooxygenase inhibitors, such as ketorolac, have no in vitro or in vivo evidence for thrombolytic potential. However, thromboxane inhibition with nonsteroidal antiinflammatory drugs may reduce platelet aggregation. Thus, once hemostasis is lost, a higher percentage of patients may progress to hematoma requiring surgical washout. Loss of platelet aggregation is illustrated well in one study that showed a benefit to ketorolac use during lower extremity free flap reconstruction. 16 This study showed fewer thrombotic flap complications with ketorolac use and no difference in hematoma rate. However, unlike anticoagulants, ketorolac is unlikely to cause a hematoma directly, although it may propagate the effects of hemostasis loss. We did not see any difference in deep venous thrombosis/pulmonary embolism diagnosis rates between the groups, but these complications are rare in outpatient surgery. Another finding without a clear physiologic cause is the increased rate of seroma seen with ketorolac compared with the control group. We found a higher rate of seroma, even when adjusting for concomitant hematoma. There is no prior link known between seroma and nonsteroidal antiinflammatory drug use; therefore, this finding should not be taken as proof of causality. Furthermore, even if true, the odds of a patient having a seroma compared with control (OR, 1.28) was low, with over 247 patients requiring intervention before an additional seroma was incurred by number needed to harm calculation. Physiologically, this could be related to the reduction in the inflammatory response, likely because of the interstitial physiology associated with leukotriene-mediated increased vascular permeability. 26 Interestingly, wound healing problems were not different between the two groups despite the difference in seroma rates. These new considerations regarding perioperative ketorolac use will require further research to clarify. This study has several limitations. The MarketScan database provides an incomplete glimpse of enrolled patients over the 5-year sample period. Interactions that do not involve billing may be incomplete, and there are a limited number of patient-specific demographics that can be obtained. In addition, inpatient records within the data set are incomplete because procedural medication injection J codes (e.g., J-1885, billing code for "injection, ketorolac tromethamine, per 15 mg") are not consistently used in the inpatient setting, as inpatient medications may be bundled in the cost of the admission. Facial rejuvenation, breast reduction, and body contouring procedures are often performed in the outpatient setting; therefore, we limited the study to outpatient operations. Prescription coverage plans are also variable in coverage for typical over-the-counter nonsteroidal antiinflammatory drugs (e.g., ibuprofen and naproxen), and use of these potentially confounding medications was difficult to track in this data set. However, the data did allow for tracking the timing of intramuscular/ intravenous ketorolac injection, approximate dosage, and subsequent complications incurred by the patient. In addition, the conclusions are likely strengthened, as surgeons refusing ketorolac postoperatively are also more likely to discourage overthe-counter nonsteroidal antiinflammatory drugs for the same reasons. The study is also limited in the ability to show causality of complications after medication delivery. For example, ketorolac may be given to a patient for pain and cause a hematoma or, conversely, the increased pain of the hematoma may necessitate the ketorolac to aid in analgesia. Given the baseline worry for increased bleeding risk of ketorolac, it may be safe to assume that ketorolac is more likely causal than confounding in this hypothetical scenario, but a definitive conclusion is not possible. Finally, this study evaluates only the intravenous administration of systemic ketorolac. Thus, the study has limited predictive power for other formulations, including topical, subcutaneous, and oral forms.
26
Overall, this large, national database study shows no correlation between ketorolac use and International Classification of Diseases, Ninth Revision, diagnosis of hematoma on multivariable logistic regression analysis. There was a small increased risk for reoperation within 72 hours of surgery, but over 262 patients would require treatment with ketorolac before any event. Given the small absolute size of the effect and number needed to harm, this effect is likely clinically unimportant. There was a small increased risk for seroma formation postoperatively, but no other evidence exists linking nonsteroidal antiinflammatory drugs to seroma physiologically; thus, we cannot interpret this finding for causality. Furthermore, ketorolac use reduced the risk and duration of readmission to the hospital, with an estimated cost savings of over $16 million across the cohort. Given ongoing concerns regarding opioid medications and the apparent safety of ketorolac in the surgical setting, ketorolac should be considered in outpatient facial rejuvenation, breast reduction, and body contouring procedures once surgical hemostasis is obtained.
